Trial Search Results

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

This study will evaluate the pharmacodynamic (PD) effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on measures of skeletal muscle function or fatigability in patients with Type II, III, or IV spinal muscular atrophy (SMA).

Stanford is currently accepting patients for this trial.

Lead Sponsor:


Collaborator: Astellas Pharma Global Development, Inc.

Stanford Investigator(s):


  • Drug: Placebo
  • Drug: Reldesemtiv 150 mg
  • Drug: Reldesemtiv 450 mg


Phase 2


Inclusion Criteria:

   - Able to comprehend and willing to sign an Informed Consent Form (ICF) for patients 18
   years of age and older. For patients less than 18 years of age, parent(s)/legal
   guardian(s) of patients must provide written informed consent prior to participation
   in the study and informed assent will be obtained from minors at least 12 years of age
   when required by regulation.

   - Males or females with genetically confirmed diagnosis of SMA who are Type II, III or
   IV and at least 12 years of age

   - Ambulatory patients, once having achieved a standing position independently, must be
   able to complete at least one lap in the 6-minute walk test (at least 50 meters)
   within 6 minutes without assistance.

   - Non-ambulatory patients (defined as individuals who are effectively requiring a
   wheelchair for all mobility needs; they may be able to stand or walk short distances,
   but unable to walk 50 meters without assistance in 6 minutes). Non-ambulatory patients
   must be able to tolerate an upright sitting position, with support, continuously for 3

   - Hammersmith (HFMS-E) score ≥ 10 and ≤ 54

   - Contracture of the elbow flexion and knee flexion ≤ 90 degrees

   - Pre-study clinical laboratory findings within the normal range or, if outside the
   normal range, deemed not clinically significant by the Investigator

   - Able to swallow an oral suspension and in the opinion of the Investigator, is expected
   to continue to be able to do so for the duration of the trial. Administration via a
   feeding tube is not allowed.

   - Forced vital capacity (FVC) > 20% predicted

   - Male patients who have reached puberty must agree to do either of the following from
   Screening until 10 weeks after the last dose of the investigational product unless
   they have had a vasectomy and confirmed sperm count is zero:

      - Abstain from sexual intercourse, OR

      - If having heterosexual intercourse, must use a condom and their female partners
      who are of childbearing potential must use a highly effective contraception

   - Female patients who have had their first period will be considered of childbearing
   potential unless they are anatomically and physiologically incapable of becoming
   pregnant. If of childbearing potential, the female patients must:

      - Have a negative urine/serum pregnancy test at Screening AND

      - Abstain from heterosexual intercourse from Screening until 10 weeks after the
      last dose of investigational product OR

      - If having heterosexual intercourse, must use a highly effective contraception
      method* and require the male partners to use a condom from Screening until 10
      weeks after the last dose of investigational product

      *Highly effective contraception methods include:

      - Established use of oral, injected or implanted hormonal methods of contraception

      - Placement of an intrauterine device (IUD) or intrauterine system (IUS)

   - Male patients must agree to refrain from sperm donation from Screening until 10 weeks
   after the final study drug administration

Exclusion Criteria:

   - History of significant hypersensitivity, intolerance, or allergy to any drug compound,
   food, or other substance, unless approved by the Investigator

   - Hospitalization within 2 months of Screening

   - History of stomach or intestinal surgery or resection that would potentially alter
   absorption and/or excretion of orally administered drugs (appendectomy, hernia repair,
   and/or cholecystectomy will be allowed)

   - A clinically significant illness within 4 weeks of Screening

   - History of alcoholism or drug addiction within 2 years prior to Screening

   - History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day
   within 3 months prior to Screening

   - Patient has used a strong CYP3A4 inhibitor within 7 days prior to first dose of study
   drug or a strong CYP3A4 inducer within 14 days prior to first dose of study drug

   - Any other medical condition that would interfere with performance of testing including
   (but not limited to) significant joint pain or arthritis limiting mobility, and
   chronic neuromuscular pain sufficient to require ongoing analgesic medication

   - Participation by two people at the same time that are living in the same household

   - Participation in any other investigational study drug trial in which receipt of an
   investigational study drug occurred within 30 days or five half-lives of the other
   investigational study drug, whichever is greater, prior to Screening

   - An ALT or AST greater than 2-fold the upper limit of normal (ULN) or has total
   bilirubin greater than the ULN at screening. These assessments may be repeated once at
   the investigator's discretion (within the screening window)

   - Currently taking nusinersen, or has taken it in the past, or plans to take it during
   the course the study

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Angelica Martinez